Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here


Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

 
Bookmark and Share
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
Diabetes News
Clinical trials testing therapies for diabetes

Latest Top (15) News


FFAR Agonist on Incretins, Insulin, Lipids and Inflammation
Conditions:   Type2 Diabetes Mellitus;   Obesity
Intervention:   Dietary Supplement: Pine nut oil
Sponsor:   Odense University Hospital
Completed - verified February 2017

Mon, 20 Feb 2017 12:00:00 EST


Radial Extracorporeal Shock Wave Therapy for Chronic Soft Tissue Wounds
Condition:   Wound of Skin
Interventions:   Device: rESWT;   Device: Sham rESWT
Sponsor:   Kuala Lumpur General Hospital
Not yet recruiting - verified February 2017

Sun, 19 Feb 2017 12:00:00 EST


Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Condition:   Non-alcoholic Fatty Liver Disease
Intervention:   Other: diabetes
Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting - verified September 2016

Sun, 19 Feb 2017 12:00:00 EST


The Application of the E-health Education on Shared Care Program for Patients With Type 2 Diabetes
Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: E-health Education;   Other: Routine care
Sponsor:   Li-Li Chen
Recruiting - verified February 2017

Sun, 19 Feb 2017 12:00:00 EST


The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus
Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: conventional treatment;   Other: Maltose app
Sponsors:   Qingdao Zhixin Health Technology Co., Ltd.;   H & J CRO International, Inc.
Recruiting - verified February 2017

Sat, 18 Feb 2017 12:00:00 EST


A Phase Ib Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus
Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BFKB8488A;   Other: Placebo
Sponsor:   Genentech, Inc.
Recruiting - verified February 2017

Fri, 17 Feb 2017 12:00:00 EST


An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
Conditions:   Atherosclerotic Cardiovascular Disease;   Symptomatic Atherosclerosis;   Type2 Diabetes;   Familial Hypercholesterolemia
Interventions:   Drug: Inclisiran;   Drug: Evolocumab
Sponsor:   The Medicines Company
Not yet recruiting - verified February 2017

Fri, 17 Feb 2017 12:00:00 EST


Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide 0.5 mg;   Drug: Semaglutide 1.0 mg;   Drug: Sitagliptin placebo;   Drug: Sitagliptin;   Drug: Semaglutide placebo 0.5 mg;   Drug: Semaglutide placebo 1.0 mg
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified February 2017

Fri, 17 Feb 2017 12:00:00 EST


Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients
Conditions:   Cancer;   Colon Cancer;   Breast Cancer;   Malignant Lymphoma
Intervention:   Drug: Chemotherapy
Sponsors:   National Cancer Center, Korea;   SMG-SNU Boramae Medical Center
Recruiting - verified February 2017

Fri, 17 Feb 2017 12:00:00 EST


Caminamos: A Smartphone App to Connect With Walking Partners
Condition:   Physical Activity
Intervention:   Other: Caminamos App
Sponsors:   Klein Buendel, Inc.;   Stanford University;   National Institute on Minority Health and Health Disparities (NIMHD)
Completed - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST


Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management
Conditions:   Ultrasonography;   Nephrolithiasis
Interventions:   Drug: CEUS;   Diagnostic Test: Non-contrast CT scan;   Diagnostic Test: Capping trial
Sponsors:   University of California, San Francisco;   Oregon Health and Science University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST


EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST


EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST


Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Condition:   Diabetic Macular Edema
Intervention:   Drug: Intravitreal Aflibercept
Sponsors:   Southeast Clinical Research Associates, LLC;   Regeneron Pharmaceuticals
Not yet recruiting - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST


Screening for Glucose Metabolism Disorders in Cardiac Rehabilitation
Condition:   Diabetes
Intervention:  
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting - verified February 2017

Thu, 16 Feb 2017 12:00:00 EST
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis
The U.S. Food and Drug Administration today cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers determine if antibiotic treatment should be started or stopped in patients with lower respiratory tract infections, such as community-acquired pneumonia, and stopped in patients with sepsis. This is the first test to use procalcitonin (PCT), a protein associated with the body’s response to a bacterial infection, as a biomarker to help make antibiotic management decisions in patients with these conditions.

Thu, 23 Feb 2017 17:30:00 -0500


FDA allows marketing of test to identify organisms that cause bloodstream infections and provide antibiotic sensitivity results
The U.S. Food and Drug Administration today allowed marketing of the PhenoTest BC Kit, performed on the Pheno System. This is the first test to identify organisms that cause bloodstream infections and provide information about which antibiotics the organism is likely to respond to (antibiotic sensitivity).

Thu, 23 Feb 2017 16:55:00 -0500


Louisiana drug and dietary supplement maker ordered to cease operations due to federal violations
On Friday, U.S. District Judge Robert G. James for the U.S. District Court for the Western District of Louisiana entered a consent decree of permanent injunction against Pick and Pay Inc./Cili Minerals, a manufacturer and distributor of drugs and dietary supplements, and its owner, Anton S. Botha, requiring the business to immediately cease operations until it comes into compliance with federal laws.

Tue, 21 Feb 2017 13:00:00 -0500


FDA approves new psoriasis drug
The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.

Wed, 15 Feb 2017 17:47:00 -0500


FDA approves drug to treat Duchenne muscular dystrophy
The U.S. Food and Drug Administration today approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

Thu, 09 Feb 2017 14:05:00 -0500


Federal judge approves consent decree with California dietary supplement distributor, Regeneca Worldwide
A California dietary supplement distributor has been ordered by a federal court to stop selling its products, which were found to contain unsafe ingredients including 1, 3-dimethylamylamine (DMAA).

Thu, 09 Feb 2017 10:47:00 -0500


FDA permits marketing of first newborn screening system for detection of four, rare metabolic disorders
FDA permits marketing of first newborn screening system for detection of four, rare metabolic disorders

Fri, 03 Feb 2017 16:32:00 -0500


FDA confirms elevated levels of belladonna in certain homeopathic teething products
The U.S. Food and Drug Administration announced today that its laboratory analysis found inconsistent amounts of belladonna, a toxic substance, in certain homeopathic teething tablets, sometimes far exceeding the amount claimed on the label. The agency is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products.

Fri, 27 Jan 2017 13:40:00 -0500


FDA approves Trulance for Chronic Idiopathic Constipation
The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.

Thu, 19 Jan 2017 16:04:00 -0500


Statement from FDA Commissioner Robert Califf, M.D. announcing FDA Oncology Center of Excellence launch
Today the U.S. Food and Drug Administration is establishing the Oncology Center of Excellence (OCE) and appointing Dr. Richard Pazdur as its director. This will make oncology the first disease area to have a coordinated clinical review of drugs, biologics and devices across the agency’s three medical product centers.

Thu, 19 Jan 2017 09:03:00 -0500
Diabetes news from the American Diabetes Association

Latest Top (5) News